Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

A. M. Menzies, M. T. Ashworth, S. Swann, R. F. Kefford, K. Flaherty, J. Weber, J. R. Infante, K. B. Kim, R. Gonzalez, O. Hamid, L. Schuchter, J. Cebon, J. A. Sosman, S. Little, P. Sun, G. Aktan, D. Ouellet, F. Jin, G. V. Long, A. Daud Melanoma Institute Australia and The University of Sydney, Sydney, Australia University of California San Francisco, San Francisco, USA GlaxoSmithKline, Collegeville, USA Westmead Hospital, University of Sydney, Sydney, Australia Westmead Millennium Institute, University of Sydney, Sydney, Australia Massachusetts General Hospital Center, Boston, USA Moffitt Cancer Center, Tampa, USA Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA California Pacific Medical Center, San Francisco, USA The University of Colorado Cancer Center, Aurora, USA The Angeles Clinic and Research Institute, Santa Monica, USA Penn Medicine, The University of Pennsylvania, Philadelphia, USA Ludwig Institute for Cancer Research, Heidelberg, Australia Vanderbilt University Medical Centre, Nashville, USA